Longitudinal quantitative proton magnetic resonance spectroscopy of the hippocampus in Alzheimer’s disease

Changes in metabolites detected by proton magnetic resonance spectroscopy (1H MRS) of the brain have been demonstrated in Alzheimer’s disease. Our objectives were, first, longitudinally to measure absolute concentrations of metabolites in both hippocampi, the sites of early Alzheimer’s disease, in p...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Brain (London, England : 1878) England : 1878), 2002-10, Vol.125 (10), p.2332-2341
Hauptverfasser: Dixon, Ruth M., Bradley, Kevin M., Budge, Marc M., Styles, Peter, Smith, A. David
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2341
container_issue 10
container_start_page 2332
container_title Brain (London, England : 1878)
container_volume 125
creator Dixon, Ruth M.
Bradley, Kevin M.
Budge, Marc M.
Styles, Peter
Smith, A. David
description Changes in metabolites detected by proton magnetic resonance spectroscopy (1H MRS) of the brain have been demonstrated in Alzheimer’s disease. Our objectives were, first, longitudinally to measure absolute concentrations of metabolites in both hippocampi, the sites of early Alzheimer’s disease, in patients with clinical Alzheimer’s disease and controls; secondly, to separate the relative contribution of atrophy and metabolite concentration change to overall signal change; and, thirdly, to determine whether metabolite concentrations in the hippocampus relate to cognitive scores. 1H MR spectra were acquired from a single voxel (12 × 15 × 25 mm3 = 4.5 ml) aligned to the long axis of each hippocampus in nine probable or possible Alzheimer’s disease subjects diagnosed according to the National Institute of Neurologic and Cognitive Disorders and Stroke (NINCDS) compared with 14 age‐matched NINCDS‐negative Alzheimer’s disease controls. Metabolite concentrations were corrected for the amount of CSF present in the voxel. Hippocampal volumes were measured at the same time. The same protocol was repeated approximately 1 year later. We found that atrophy‐ corrected hippocampal N‐acetylaspartate (NAA) concentration was lower in cognitively impaired subjects compared with controls. This was significant for the left hippocampus (baseline 87% of control, P = 0.013; and at 1 year 76% of control, P = 0.020). Hippocampal volumes also differed significantly between the groups, and decreased significantly over 1 year in the Alzheimer’s disease group (12%, P = 0.017). The decrease in [NAA] over 1 year was not significant in either group. Discriminant analysis revealed that the best classification of subjects was by including both left NAA concentration and left hippocampal volume. myo‐Inositol signals from these small voxels had poor signal‐to‐noise and demonstrated no significant changes. We conclude that 1HMRS‐detectable metabolites can be quantified from the hippocampi of cognitively impaired individuals, and that hippocampal [NAA] is significantly reduced in Alzheimer’s disease, in excess of atrophy. In our cohort, the differences were more significant for the left hippocampus.
doi_str_mv 10.1093/brain/awf226
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72115610</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>72115610</sourcerecordid><originalsourceid>FETCH-LOGICAL-c451t-7f4610984a09625a15e8877add1ae641cdd16e4d5bb7208ddada3d1000d92a503</originalsourceid><addsrcrecordid>eNqF0U1rFDEYB_BBFLut3jxLEOzJsUkmLzPHslgrLHioL8VLeDbJdFNnkmmSUevJr-HX85OYdRcLXjzlgfx44Pn_q-oJwS8J7pqTdQTnT-BrT6m4Vy0IE7imhIv71QJjLOq24_igOkzpGmPCGioeVgeEUsZw2y2qYRX8lcuzcR4GdDODzy5Ddl8smmLIwaMRrrzNTqNoU_DgtUVpsjrHkHSYblHoUd5YtHHTFDSM05yQ8-h0-L6xbrTx14-fCRmXLCT7qHrQw5Ds4_17VL0_e_VueV6v3r5-szxd1ZpxkmvZM1FOaxngTlAOhNu2lRKMIWAFI7oMwjLD12tJcWsMGGgMKdeajgLHzVF1vNtbTriZbcpqdEnbYQBvw5yUpKQERP4PScd41xFZ4LN_4HWYY4lsazijAuMterFDumSTou3VFN0I8VYRrLZdqT9dqV1XhT_d75zXozV3eF9OAc_3AJKGoY8lfJfuXNNRKdl2Ub1zLmX77e8_xM9KyEZydX75SV3wyw_Lj2cXSjS_AUzgr-g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>195426007</pqid></control><display><type>article</type><title>Longitudinal quantitative proton magnetic resonance spectroscopy of the hippocampus in Alzheimer’s disease</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Dixon, Ruth M. ; Bradley, Kevin M. ; Budge, Marc M. ; Styles, Peter ; Smith, A. David</creator><creatorcontrib>Dixon, Ruth M. ; Bradley, Kevin M. ; Budge, Marc M. ; Styles, Peter ; Smith, A. David</creatorcontrib><description>Changes in metabolites detected by proton magnetic resonance spectroscopy (1H MRS) of the brain have been demonstrated in Alzheimer’s disease. Our objectives were, first, longitudinally to measure absolute concentrations of metabolites in both hippocampi, the sites of early Alzheimer’s disease, in patients with clinical Alzheimer’s disease and controls; secondly, to separate the relative contribution of atrophy and metabolite concentration change to overall signal change; and, thirdly, to determine whether metabolite concentrations in the hippocampus relate to cognitive scores. 1H MR spectra were acquired from a single voxel (12 × 15 × 25 mm3 = 4.5 ml) aligned to the long axis of each hippocampus in nine probable or possible Alzheimer’s disease subjects diagnosed according to the National Institute of Neurologic and Cognitive Disorders and Stroke (NINCDS) compared with 14 age‐matched NINCDS‐negative Alzheimer’s disease controls. Metabolite concentrations were corrected for the amount of CSF present in the voxel. Hippocampal volumes were measured at the same time. The same protocol was repeated approximately 1 year later. We found that atrophy‐ corrected hippocampal N‐acetylaspartate (NAA) concentration was lower in cognitively impaired subjects compared with controls. This was significant for the left hippocampus (baseline 87% of control, P = 0.013; and at 1 year 76% of control, P = 0.020). Hippocampal volumes also differed significantly between the groups, and decreased significantly over 1 year in the Alzheimer’s disease group (12%, P = 0.017). The decrease in [NAA] over 1 year was not significant in either group. Discriminant analysis revealed that the best classification of subjects was by including both left NAA concentration and left hippocampal volume. myo‐Inositol signals from these small voxels had poor signal‐to‐noise and demonstrated no significant changes. We conclude that 1HMRS‐detectable metabolites can be quantified from the hippocampi of cognitively impaired individuals, and that hippocampal [NAA] is significantly reduced in Alzheimer’s disease, in excess of atrophy. In our cohort, the differences were more significant for the left hippocampus.</description><identifier>ISSN: 0006-8950</identifier><identifier>ISSN: 1460-2156</identifier><identifier>EISSN: 1460-2156</identifier><identifier>DOI: 10.1093/brain/awf226</identifier><identifier>PMID: 12244089</identifier><identifier>CODEN: BRAIAK</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>1H MRS = proton magnetic resonance spectroscopy ; Aged ; Aged, 80 and over ; Alzheimer Disease - pathology ; Alzheimer Disease - psychology ; Biological and medical sciences ; CAMCOG = Cambridge cognitive examination ; Cho = choline ; Cr = creatine ; Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases ; dementia ; Female ; Hippocampus - pathology ; Humans ; Longitudinal Studies ; Magnetic Resonance Spectroscopy - methods ; Magnetic Resonance Spectroscopy - statistics &amp; numerical data ; Male ; medial temporal lobe ; Medical sciences ; Middle Aged ; MI = myo‐inositol ; MMSE = Mini‐Mental State Examination ; NAA = N‐acetylaspartate ; neurodegeneration ; Neurology ; NINCDS = National Institute of Neurologic and Cognitive Disorders and Stroke ; proton MRS ; Protons ; Statistics, Nonparametric</subject><ispartof>Brain (London, England : 1878), 2002-10, Vol.125 (10), p.2332-2341</ispartof><rights>2002 INIST-CNRS</rights><rights>Copyright Oxford University Press(England) Oct 2002</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c451t-7f4610984a09625a15e8877add1ae641cdd16e4d5bb7208ddada3d1000d92a503</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=13927746$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12244089$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dixon, Ruth M.</creatorcontrib><creatorcontrib>Bradley, Kevin M.</creatorcontrib><creatorcontrib>Budge, Marc M.</creatorcontrib><creatorcontrib>Styles, Peter</creatorcontrib><creatorcontrib>Smith, A. David</creatorcontrib><title>Longitudinal quantitative proton magnetic resonance spectroscopy of the hippocampus in Alzheimer’s disease</title><title>Brain (London, England : 1878)</title><addtitle>Brain</addtitle><description>Changes in metabolites detected by proton magnetic resonance spectroscopy (1H MRS) of the brain have been demonstrated in Alzheimer’s disease. Our objectives were, first, longitudinally to measure absolute concentrations of metabolites in both hippocampi, the sites of early Alzheimer’s disease, in patients with clinical Alzheimer’s disease and controls; secondly, to separate the relative contribution of atrophy and metabolite concentration change to overall signal change; and, thirdly, to determine whether metabolite concentrations in the hippocampus relate to cognitive scores. 1H MR spectra were acquired from a single voxel (12 × 15 × 25 mm3 = 4.5 ml) aligned to the long axis of each hippocampus in nine probable or possible Alzheimer’s disease subjects diagnosed according to the National Institute of Neurologic and Cognitive Disorders and Stroke (NINCDS) compared with 14 age‐matched NINCDS‐negative Alzheimer’s disease controls. Metabolite concentrations were corrected for the amount of CSF present in the voxel. Hippocampal volumes were measured at the same time. The same protocol was repeated approximately 1 year later. We found that atrophy‐ corrected hippocampal N‐acetylaspartate (NAA) concentration was lower in cognitively impaired subjects compared with controls. This was significant for the left hippocampus (baseline 87% of control, P = 0.013; and at 1 year 76% of control, P = 0.020). Hippocampal volumes also differed significantly between the groups, and decreased significantly over 1 year in the Alzheimer’s disease group (12%, P = 0.017). The decrease in [NAA] over 1 year was not significant in either group. Discriminant analysis revealed that the best classification of subjects was by including both left NAA concentration and left hippocampal volume. myo‐Inositol signals from these small voxels had poor signal‐to‐noise and demonstrated no significant changes. We conclude that 1HMRS‐detectable metabolites can be quantified from the hippocampi of cognitively impaired individuals, and that hippocampal [NAA] is significantly reduced in Alzheimer’s disease, in excess of atrophy. In our cohort, the differences were more significant for the left hippocampus.</description><subject>1H MRS = proton magnetic resonance spectroscopy</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Alzheimer Disease - pathology</subject><subject>Alzheimer Disease - psychology</subject><subject>Biological and medical sciences</subject><subject>CAMCOG = Cambridge cognitive examination</subject><subject>Cho = choline</subject><subject>Cr = creatine</subject><subject>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</subject><subject>dementia</subject><subject>Female</subject><subject>Hippocampus - pathology</subject><subject>Humans</subject><subject>Longitudinal Studies</subject><subject>Magnetic Resonance Spectroscopy - methods</subject><subject>Magnetic Resonance Spectroscopy - statistics &amp; numerical data</subject><subject>Male</subject><subject>medial temporal lobe</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>MI = myo‐inositol</subject><subject>MMSE = Mini‐Mental State Examination</subject><subject>NAA = N‐acetylaspartate</subject><subject>neurodegeneration</subject><subject>Neurology</subject><subject>NINCDS = National Institute of Neurologic and Cognitive Disorders and Stroke</subject><subject>proton MRS</subject><subject>Protons</subject><subject>Statistics, Nonparametric</subject><issn>0006-8950</issn><issn>1460-2156</issn><issn>1460-2156</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqF0U1rFDEYB_BBFLut3jxLEOzJsUkmLzPHslgrLHioL8VLeDbJdFNnkmmSUevJr-HX85OYdRcLXjzlgfx44Pn_q-oJwS8J7pqTdQTnT-BrT6m4Vy0IE7imhIv71QJjLOq24_igOkzpGmPCGioeVgeEUsZw2y2qYRX8lcuzcR4GdDODzy5Ddl8smmLIwaMRrrzNTqNoU_DgtUVpsjrHkHSYblHoUd5YtHHTFDSM05yQ8-h0-L6xbrTx14-fCRmXLCT7qHrQw5Ds4_17VL0_e_VueV6v3r5-szxd1ZpxkmvZM1FOaxngTlAOhNu2lRKMIWAFI7oMwjLD12tJcWsMGGgMKdeajgLHzVF1vNtbTriZbcpqdEnbYQBvw5yUpKQERP4PScd41xFZ4LN_4HWYY4lsazijAuMterFDumSTou3VFN0I8VYRrLZdqT9dqV1XhT_d75zXozV3eF9OAc_3AJKGoY8lfJfuXNNRKdl2Ub1zLmX77e8_xM9KyEZydX75SV3wyw_Lj2cXSjS_AUzgr-g</recordid><startdate>20021001</startdate><enddate>20021001</enddate><creator>Dixon, Ruth M.</creator><creator>Bradley, Kevin M.</creator><creator>Budge, Marc M.</creator><creator>Styles, Peter</creator><creator>Smith, A. David</creator><general>Oxford University Press</general><general>Oxford Publishing Limited (England)</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7QR</scope><scope>7TK</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20021001</creationdate><title>Longitudinal quantitative proton magnetic resonance spectroscopy of the hippocampus in Alzheimer’s disease</title><author>Dixon, Ruth M. ; Bradley, Kevin M. ; Budge, Marc M. ; Styles, Peter ; Smith, A. David</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c451t-7f4610984a09625a15e8877add1ae641cdd16e4d5bb7208ddada3d1000d92a503</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>1H MRS = proton magnetic resonance spectroscopy</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Alzheimer Disease - pathology</topic><topic>Alzheimer Disease - psychology</topic><topic>Biological and medical sciences</topic><topic>CAMCOG = Cambridge cognitive examination</topic><topic>Cho = choline</topic><topic>Cr = creatine</topic><topic>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</topic><topic>dementia</topic><topic>Female</topic><topic>Hippocampus - pathology</topic><topic>Humans</topic><topic>Longitudinal Studies</topic><topic>Magnetic Resonance Spectroscopy - methods</topic><topic>Magnetic Resonance Spectroscopy - statistics &amp; numerical data</topic><topic>Male</topic><topic>medial temporal lobe</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>MI = myo‐inositol</topic><topic>MMSE = Mini‐Mental State Examination</topic><topic>NAA = N‐acetylaspartate</topic><topic>neurodegeneration</topic><topic>Neurology</topic><topic>NINCDS = National Institute of Neurologic and Cognitive Disorders and Stroke</topic><topic>proton MRS</topic><topic>Protons</topic><topic>Statistics, Nonparametric</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dixon, Ruth M.</creatorcontrib><creatorcontrib>Bradley, Kevin M.</creatorcontrib><creatorcontrib>Budge, Marc M.</creatorcontrib><creatorcontrib>Styles, Peter</creatorcontrib><creatorcontrib>Smith, A. David</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Brain (London, England : 1878)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dixon, Ruth M.</au><au>Bradley, Kevin M.</au><au>Budge, Marc M.</au><au>Styles, Peter</au><au>Smith, A. David</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Longitudinal quantitative proton magnetic resonance spectroscopy of the hippocampus in Alzheimer’s disease</atitle><jtitle>Brain (London, England : 1878)</jtitle><addtitle>Brain</addtitle><date>2002-10-01</date><risdate>2002</risdate><volume>125</volume><issue>10</issue><spage>2332</spage><epage>2341</epage><pages>2332-2341</pages><issn>0006-8950</issn><issn>1460-2156</issn><eissn>1460-2156</eissn><coden>BRAIAK</coden><abstract>Changes in metabolites detected by proton magnetic resonance spectroscopy (1H MRS) of the brain have been demonstrated in Alzheimer’s disease. Our objectives were, first, longitudinally to measure absolute concentrations of metabolites in both hippocampi, the sites of early Alzheimer’s disease, in patients with clinical Alzheimer’s disease and controls; secondly, to separate the relative contribution of atrophy and metabolite concentration change to overall signal change; and, thirdly, to determine whether metabolite concentrations in the hippocampus relate to cognitive scores. 1H MR spectra were acquired from a single voxel (12 × 15 × 25 mm3 = 4.5 ml) aligned to the long axis of each hippocampus in nine probable or possible Alzheimer’s disease subjects diagnosed according to the National Institute of Neurologic and Cognitive Disorders and Stroke (NINCDS) compared with 14 age‐matched NINCDS‐negative Alzheimer’s disease controls. Metabolite concentrations were corrected for the amount of CSF present in the voxel. Hippocampal volumes were measured at the same time. The same protocol was repeated approximately 1 year later. We found that atrophy‐ corrected hippocampal N‐acetylaspartate (NAA) concentration was lower in cognitively impaired subjects compared with controls. This was significant for the left hippocampus (baseline 87% of control, P = 0.013; and at 1 year 76% of control, P = 0.020). Hippocampal volumes also differed significantly between the groups, and decreased significantly over 1 year in the Alzheimer’s disease group (12%, P = 0.017). The decrease in [NAA] over 1 year was not significant in either group. Discriminant analysis revealed that the best classification of subjects was by including both left NAA concentration and left hippocampal volume. myo‐Inositol signals from these small voxels had poor signal‐to‐noise and demonstrated no significant changes. We conclude that 1HMRS‐detectable metabolites can be quantified from the hippocampi of cognitively impaired individuals, and that hippocampal [NAA] is significantly reduced in Alzheimer’s disease, in excess of atrophy. In our cohort, the differences were more significant for the left hippocampus.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><pmid>12244089</pmid><doi>10.1093/brain/awf226</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0006-8950
ispartof Brain (London, England : 1878), 2002-10, Vol.125 (10), p.2332-2341
issn 0006-8950
1460-2156
1460-2156
language eng
recordid cdi_proquest_miscellaneous_72115610
source MEDLINE; Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals
subjects 1H MRS = proton magnetic resonance spectroscopy
Aged
Aged, 80 and over
Alzheimer Disease - pathology
Alzheimer Disease - psychology
Biological and medical sciences
CAMCOG = Cambridge cognitive examination
Cho = choline
Cr = creatine
Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases
dementia
Female
Hippocampus - pathology
Humans
Longitudinal Studies
Magnetic Resonance Spectroscopy - methods
Magnetic Resonance Spectroscopy - statistics & numerical data
Male
medial temporal lobe
Medical sciences
Middle Aged
MI = myo‐inositol
MMSE = Mini‐Mental State Examination
NAA = N‐acetylaspartate
neurodegeneration
Neurology
NINCDS = National Institute of Neurologic and Cognitive Disorders and Stroke
proton MRS
Protons
Statistics, Nonparametric
title Longitudinal quantitative proton magnetic resonance spectroscopy of the hippocampus in Alzheimer’s disease
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T17%3A57%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Longitudinal%20quantitative%20proton%20magnetic%20resonance%20spectroscopy%20of%20the%20hippocampus%20in%20Alzheimer%E2%80%99s%20disease&rft.jtitle=Brain%20(London,%20England%20:%201878)&rft.au=Dixon,%20Ruth%20M.&rft.date=2002-10-01&rft.volume=125&rft.issue=10&rft.spage=2332&rft.epage=2341&rft.pages=2332-2341&rft.issn=0006-8950&rft.eissn=1460-2156&rft.coden=BRAIAK&rft_id=info:doi/10.1093/brain/awf226&rft_dat=%3Cproquest_cross%3E72115610%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=195426007&rft_id=info:pmid/12244089&rfr_iscdi=true